One day, we won't need to call it "women's health"
A decade ago, "green chemistry" was a hard sell — now it's just how chemistry gets done. Drawing on that shift, here's why women's health is on the same trajectory, and what regulation, funding data, and momentum tell us about how fast it could get there. Reflection from our attendance to Women’s Health Horizons conference in London.
The risk in having too many risks…
Confusing failure modes for risks is one of the most common structural mistakes in medical device risk analysis — and one of the most costly to fix later. This article explains the difference between hazards, hazardous situations, and harm under ISO 14971, why a bloated risk analysis undermines your whole risk management process, and how one simple syntax rule can help you build a cleaner, more actionable document from the start.
The next strategic frontiers of medtech
Where should medtech and femtech companies focus their international expansion efforts after establishing EU and US market presence? This article analyses eight high-potential markets across four global regions — Anglosphere, East Asia, MENA, and Latin America — ranked against three strategic criteria: ROI and medtech infrastructure, femtech readiness, and regulatory alignment with international harmonisation frameworks including MDSAP and CE Mark mutual recognition agreements. Whether you are mapping your next regulatory strategy or building a market entry roadmap, this evidence-based analysis offers a practical starting point — with an honest look at what the data says and where gut instinct still has a role to play.
Quantum: The Regulatory Frontier That Will Catch Us Off Guard
Quantum computing is revolutionizing medical device development, but regulatory frameworks aren't ready. Companies like Algorithmiq are achieving 100x precision improvements in cancer therapy using quantum-generated synthetic data—yet FDA's 2025 AI/ML guidance doesn't address quantum validation challenges. How do you validate data you can't reproduce classically? Regulatory science needs quantum-aware frameworks now, before quantum-AI medical devices reach the clinic.
Beyond the EU-US paradigm
The global medtech regulatory landscape is shifting away from the traditional EU-US duopoly. The UAE now offers approval timelines 30-50% shorter than US and EU markets, while Mexico and Nigeria introduced comprehensive digital health regulations in 2023 and 2025. Canada, Australia, the UK, and Brazil are implementing bold reforms—from the UK's AI Airlock regulatory sandbox to Brazil's platform tracking over 500 registered software medical devices. This analysis explores strategic implications for medtech companies choosing between the Anglosphere, BRIC nations, Middle East markets, and emerging economies for regulatory submissions.
Plasters Vs Period Products
Why are tampons regulated differently than plasters? Discover the critical gap between "hygiene products" and Class I Medical Devices (MDR). From ISO 13485 quality standards and biocompatibility testing to the FDA’s Class II classification, we explore why medical-grade manufacturing—like Daye’s cleanroom production—is essential for menstrual safety.
PFAS: wait-and-see Vs precautionary principle
When data is limited, do you default to safety or wait for proof of harm? This post explores the widening regulatory gap between the US and EU regarding PFAS - the "Forever Chemicals."
Crans-Montana, a compliance perspective
In the wake of the devastating NYE fire in Crans-Montana, this post reflects on the critical role of compliance and individual accountability in preventing national tragedies, reminding us that regulation is only a burden until the moment it becomes our last line of defense.
FDA’s new guidance on general wellness
This post critiques the widening regulatory gap between the US and EU following the FDA's new wellness guidance, highlighting how lower barriers for bold health claims in the US may sacrifice essential quality drivers and complicate global strategies for startups.
MDR/IVDR proposal for simplication
This post highlights the European Commission's groundbreaking proposal to overhaul and simplify the MDR and IVDR frameworks, promising more proportionate rules for low-risk devices, reduced administrative burdens for SMEs, and a modern, digital-first approach to medtech regulation in the EU.
What can we learn from… Canada?
This post explores the "Canadian Technology Accelerator" model for international expansion, sharing insights from a bilingual FemTech panel in Paris on how high-potential startups - like PCOS-focused mentee Élan Healthcare - can leverage diplomatic networks and local mentorship to navigate global regulatory compliance.
At Women’s Health Week Europe
The go-to regulatory compliance agency for femtech. Find out more.
